Serigne N Lo1,2, Richard A Scolyer1,2,3, John F Thompson4,5,6. 1. Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia. 2. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. 3. Royal Prince Alfred Hospital, Camperdown, NSW, Australia. 4. Melanoma Institute Australia, The University of Sydney, North Sydney, NSW, Australia. john.thompson@melanoma.org.au. 5. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. john.thompson@melanoma.org.au. 6. Royal Prince Alfred Hospital, Camperdown, NSW, Australia. john.thompson@melanoma.org.au.
Abstract
BACKGROUND: Counterintuitively, more deaths from melanoma occur among patients with thin (T1) primary melanomas (≤ 1 mm) than among those with thick primary melanoma because the great majority present with T1 tumors. Therefore, it is important to stratify their risk as accurately as possible to guide their management and follow-up. This study sought to explore the relationship between tumor thickness and prognosis for patients with thin primary melanomas. METHODS: A retrospective, single-institution study investigated 6263 patients with cutaneous melanoma (including 2117 T1 cases) who had a minimum follow-up period of 10 years. RESULTS: For the entire patient cohort, the 10-year melanoma-specific survival (MSS) rate ranged between 92% for the patients with primary melanomas up to 0.3 mm thick and 32% for those with melanomas thicker than 8 mm. When divided into 25-quantile-thickness groups there was a significant difference in 10-year MSS between the two consecutive groups 0.8 and 0.9 mm; the differences in survival were not significantly different for any other consecutive cut points within the less than or equal to 1 mm thickness range, indicating a biologically-relevant difference in outcome above and below 0.8 mm. For the patients treated initially at the authors' institution, the 10- and 20-year MSS rates for those with tumors up to 0.8 mm thick were respectively 93.4 and 85.7%, and for tumors 0.9 to 1.0 mm, the rates were respectively 81.1 and 71.4%. Only 29.3% of the T1 patients who died of melanoma were deceased within 5 years. CONCLUSIONS: A naturally occurring thickness cut point of 0.8 mm predicts higher or lower risk for patients with thin primary cutaneous melanomas. Long-term follow-up assessment of patients with T1 melanoma is important because late mortality due to melanoma is more common than early mortality.
BACKGROUND: Counterintuitively, more deaths from melanoma occur among patients with thin (T1) primary melanomas (≤ 1 mm) than among those with thick primary melanoma because the great majority present with T1 tumors. Therefore, it is important to stratify their risk as accurately as possible to guide their management and follow-up. This study sought to explore the relationship between tumor thickness and prognosis for patients with thin primary melanomas. METHODS: A retrospective, single-institution study investigated 6263 patients with cutaneous melanoma (including 2117 T1 cases) who had a minimum follow-up period of 10 years. RESULTS: For the entire patient cohort, the 10-year melanoma-specific survival (MSS) rate ranged between 92% for the patients with primary melanomas up to 0.3 mm thick and 32% for those with melanomas thicker than 8 mm. When divided into 25-quantile-thickness groups there was a significant difference in 10-year MSS between the two consecutive groups 0.8 and 0.9 mm; the differences in survival were not significantly different for any other consecutive cut points within the less than or equal to 1 mm thickness range, indicating a biologically-relevant difference in outcome above and below 0.8 mm. For the patients treated initially at the authors' institution, the 10- and 20-year MSS rates for those with tumors up to 0.8 mm thick were respectively 93.4 and 85.7%, and for tumors 0.9 to 1.0 mm, the rates were respectively 81.1 and 71.4%. Only 29.3% of the T1 patients who died of melanoma were deceased within 5 years. CONCLUSIONS: A naturally occurring thickness cut point of 0.8 mm predicts higher or lower risk for patients with thin primary cutaneous melanomas. Long-term follow-up assessment of patients with T1 melanoma is important because late mortality due to melanoma is more common than early mortality.
Authors: Andrea Maurichi; Rosalba Miceli; Hanna Eriksson; Julia Newton-Bishop; Jérémie Nsengimana; May Chan; Andrew J Hayes; Kara Heelan; David Adams; Roberto Patuzzo; Francesco Barretta; Gianfranco Gallino; Catherine Harwood; Daniele Bergamaschi; Dorothy Bennett; Konstantinos Lasithiotakis; Paola Ghiorzo; Bruna Dalmasso; Ausilia Manganoni; Francesca Consoli; Ilaria Mattavelli; Consuelo Barbieri; Andrea Leva; Umberto Cortinovis; Vittoria Espeli; Cristina Mangas; Pietro Quaglino; Simone Ribero; Paolo Broganelli; Giovanni Pellacani; Caterina Longo; Corrado Del Forno; Lorenzo Borgognoni; Serena Sestini; Nicola Pimpinelli; Sara Fortunato; Alessandra Chiarugi; Paolo Nardini; Elena Morittu; Antonio Florita; Mara Cossa; Barbara Valeri; Massimo Milione; Giancarlo Pruneri; Odysseas Zoras; Andrea Anichini; Roberta Mortarini; Mario Santinami Journal: J Clin Oncol Date: 2020-03-13 Impact factor: 44.544
Authors: Douglas Grossman; Nwanneka Okwundu; Edmund K Bartlett; Michael A Marchetti; Megan Othus; Daniel G Coit; Rebecca I Hartman; Sancy A Leachman; Elizabeth G Berry; Larissa Korde; Sandra J Lee; Menashe Bar-Eli; Marianne Berwick; Tawnya Bowles; Elizabeth I Buchbinder; Elizabeth M Burton; Emily Y Chu; Clara Curiel-Lewandrowski; Julia A Curtis; Adil Daud; Dekker C Deacon; Laura K Ferris; Jeffrey E Gershenwald; Kenneth F Grossmann; Siwen Hu-Lieskovan; John Hyngstrom; Joanne M Jeter; Robert L Judson-Torres; Kari L Kendra; Caroline C Kim; John M Kirkwood; David H Lawson; Philip D Leming; Georgina V Long; Ashfaq A Marghoob; Janice M Mehnert; Michael E Ming; Kelly C Nelson; David Polsky; Richard A Scolyer; Eric A Smith; Vernon K Sondak; Mitchell S Stark; Jennifer A Stein; John A Thompson; John F Thompson; Suraj S Venna; Maria L Wei; Susan M Swetter Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282
Authors: E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino Journal: Cancer Cell Date: 2021-02-04 Impact factor: 31.743
Authors: Qiuying Ma; Huinan Suo; Li Zhu; Yue Qian; Xiaoyan Sun; Jun Xie; Qianru Li; Yangxue Fu; Jun Li; Juan Tao Journal: Cancer Med Date: 2020-05-05 Impact factor: 4.452
Authors: Mariusz Sikora; Lidia Rudnicka; Barbara Borkowska; Agnieszka Kardynał; Monika Słowińska; Adriana Rakowska; Olga Warszawik-Hendzel; Anna Wiergowska; Iwona Ługowska; Piotr Rutkowski; Tadeusz Dębniak; Jan Lubiński; Małgorzata Olszewska Journal: J Cancer Date: 2018-08-06 Impact factor: 4.207
Authors: Lazaro Hiram Betancourt; Jeovanis Gil; Yonghyo Kim; Viktória Doma; Uğur Çakır; Aniel Sanchez; Jimmy Rodriguez Murillo; Magdalena Kuras; Indira Pla Parada; Yutaka Sugihara; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Erika Velasquez; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Krzysztof Pawłowski; Jonatan Eriksson; Beáta Szeitz; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Runyu Hong; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Qimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Peter Horvath; Leticia Szadai; József Tímár; Sarolta Kárpáti; A Marcell Szász; Johan Malm; David Fenyö; Henrik Ekedahl; István Balázs Németh; György Marko-Varga Journal: Clin Transl Med Date: 2021-07